BioMérieux, a provider of in vitro diagnostics, completed the £70m investment in Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology. “With bioMérieux's strategic investment and our shared commitment to innovation, we are poised to accelerate the development of nanopore-based IVD solutions. This investment will enable us to deliver rapid, accessible, and affordable clinical tools more quickly to address unmet needs and improve healthcare worldwide,” Gordon Sanghera, Oxford Nanopore Technologies CEO.